AptarGroup (ATR) AI Stock Analysis

• Market Cap: $7.79B
• Dividend Yield: 1.5%
• Average Volume (3M): 519.48K
• Price to Earnings (P/E): 20.4
• Beta (1Y): 0.57
• Revenue Growth: 2.50%
• EPS Growth: 25.05%
• Country: US
• Employees: 13,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.25
• Shares Outstanding: 64,379,740
• 10 Day Avg. Volume: 536,595
• 30 Day Avg. Volume: 519,482
• PEG Ratio: 3.60
• Price to Book (P/B): 3.01
• Price to Sales (P/S): 2.12
• P/FCF Ratio: 26.76
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 2.40
• Enterprise Value/Gross Profit: 8.12
• Enterprise Value/Ebitda: 10.91
• 1Y Price Target: $154.25
• Price Target Upside: 27.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 5.59
• Revenue Forecast (FY): $3.92B

• Rating: 65 Neutral
• Price Target: $139.00 ▲(14.82% Upside)
• Action: Downgraded Date: 03/18/26
• Date: Action: Downgraded 03/18/26

The score is driven primarily by solid financial performance (steady growth, resilient margins, and manageable leverage), partially offset by weak technical momentum (below key moving averages with negative MACD). Valuation is reasonable, while the latest earnings call and CEO transition add a mixed but generally stable backdrop due to reaffirmed guidance, productivity actions, and buybacks versus near-term margin and cost headwinds.

Positive Factors

Pharma pipeline & approvals

Regulatory approvals (e.g., CARDAMYST) and multiple Pharma partnerships signal durable, validation-driven wins. Regulatory-grade device supply and long qualification cycles create multi-year commercial commitments, high switching costs and predictable revenue from commercialized drug programs.

Healthy cash generation & leverage

Consistent operating cash flow and manageable net debt provide durable financial flexibility. Healthy cash generation funds capex, productivity initiatives and the $600M buyback while supporting commercialization investments and buffering near-term margin cyclical pressures.

Tooling sales and customer wins

Record tooling and marquee customer wins strengthen customer retention and create embedded supply relationships. Tooling builds switching costs and recurring aftermarket supply, supporting multi-year revenue streams and cross-sell opportunities across Beauty, Closures and Pharma segments.

Negative Factors

Emergency medicine destocking

A ~$65M destocking impact concentrated in H1 reduces high-margin Pharma revenue and compresses near-term profitability. Even if temporary, the timing can delay margin recovery, weaken cash flow cadence and complicate resource allocation for commercialization and productivity investments.

Margin compression from ops issues

Material margin declines driven by product mix and production impacts in Beauty and Closures reflect execution risk. Supplier disruptions, plant environmental upgrades and unscheduled downtime raise operating costs and capex needs, threatening margin sustainability until operational fixes are fully implemented.

Free cash flow volatility

A meaningful FCF decline and noted volatility (tax timing, pension contributions, working capital shifts) reduce spare liquidity. In combination with higher capex and interest-raising financings, inconsistent cash conversion can limit discretionary actions or slow deleveraging under extended industry softness.

AptarGroup Business Overview & Revenue Model

Company Description

AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

How the Company Makes Money

AptarGroup makes money primarily by manufacturing and selling proprietary dispensing, closure, and drug-delivery components to business customers (e.g., pharmaceutical companies and consumer packaged goods brand owners). Its revenue model is largely product-based: customers purchase high-volume, repeat-use components that are integrated into the customer’s finished product packaging or drug-delivery system, creating recurring demand tied to the customer’s end-product sales and production volumes. A key earnings driver is the Healthcare segment, where Aptar supplies drug-delivery devices and components (for example, systems used to administer nasal, pulmonary/inhalation, and injectable therapies). These programs often require specialized engineering, regulatory-grade manufacturing, validation, and long qualification cycles; once designed into a drug product, the components can generate steady, multi-year revenue through ongoing commercial supply. In its Beauty and Home and Food and Beverage businesses, Aptar sells dispensing pumps, actuators, sprayers, aerosol valves, and closures that brand owners use to differentiate products and improve usability; revenue is generated from supplying these parts at scale, often on a recurring basis for established product lines. Across segments, Aptar’s earnings are supported by long-term customer relationships, custom design-and-development work that can lead to higher-value proprietary solutions, and scale manufacturing that benefits from global production and the breadth of its dispensing technology portfolio. Specific partner names, contract structures, or segment revenue percentages: null.

AptarGroup Financial Statement Overview

Summary

Strong overall quality: steady multi-year revenue growth and improved profitability (net margin ~10% in 2024–2025; EBITDA margin ~19–22%). Balance sheet leverage is moderate (debt-to-equity ~0.44; leverage ratio 1.38) with healthy ROE in recent years. Main offsets are modest recent growth (~3% in 2025) and some free-cash-flow volatility with a 2025 pullback.

Income Statement

Revenue has grown steadily from 2020 to 2025 (about $2.93B to $3.78B), with low-to-mid single-digit growth in the last two years. Profitability improved versus 2022–2023, with net margin around 10% in 2024–2025 and EBITDA margin holding near ~19–22%, supporting solid earnings quality for the industry. The main weakness is that growth is not consistently strong (2025 growth ~3%), and some 2025 margin fields appear unavailable in the data, limiting year-to-year margin comparability.

Balance Sheet

Leverage looks manageable based on 2024 debt relative to equity (debt-to-equity ~0.44) and rising equity over time, indicating improving balance-sheet capacity. Returns to shareholders are healthy in 2023–2024 (return on equity in the low-to-mid teens), consistent with a profitable, established operator. A key risk is that total debt remains sizable (roughly $1.1B–$1.2B across the period), and some 2025 leverage/return fields are unavailable, which reduces visibility into the most recent balance-sheet trajectory.

Cash Flow

Operating cash flow is consistently positive and robust (roughly $480M–$640M in 2022–2024 and ~$570M in 2025), and free cash flow has generally been meaningfully positive. However, free cash flow has been volatile: strong gains in 2022–2024 followed by a modest decline in 2025 (free cash flow down slightly year over year), and several 2025 cash conversion metrics are unavailable, limiting assessment of how well cash generation tracked earnings most recently.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.78B	3.58B	3.49B	3.32B	3.23B
Gross Profit	1.12B	1.36B	1.26B	1.16B	1.16B
EBITDA	831.48M	777.45M	663.84M	609.41M	586.79M
Net Income	392.79M	374.54M	284.49M	239.29M	244.10M
Balance Sheet
Total Assets	5.25B	4.43B	4.45B	4.20B	4.14B
Cash, Cash Equivalents and Short-Term Investments	409.53M	226.18M	223.64M	141.73M	123.67M
Total Debt	1.53B	1.08B	1.18B	1.22B	1.24B
Total Liabilities	2.54B	1.95B	2.13B	2.14B	2.16B
Stockholders Equity	2.67B	2.47B	2.31B	2.05B	1.97B
Cash Flow
Free Cash Flow	299.58M	349.22M	256.84M	163.00M	55.51M
Operating Cash Flow	570.00M	643.41M	575.24M	478.62M	363.44M
Investing Cash Flow	-330.64M	-396.72M	-324.46M	-295.64M	-457.24M
Financing Cash Flow	-78.26M	-225.34M	-171.55M	-162.10M	-81.52M

AptarGroup Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 121.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATR, the sentiment is Negative. The current price of 121.06 is below the 20-day moving average (MA) of 134.38, below the 50-day MA of 131.67, and below the 200-day MA of 134.17, indicating a bearish trend. The MACD of -2.90 indicates Positive momentum. The RSI at 26.69 is Positive, neither overbought nor oversold. The STOCH value of 15.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATR.

AptarGroup Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WST	72 Outperform	$17.07B	40.29	16.68%	0.32%	4.90%	-0.26%
COO	69 Neutral	$13.65B	30.60	4.83%	―	5.06%	-4.47%
ATR	65 Neutral	$7.79B	20.41	14.67%	1.50%	2.50%	25.05%
STVN	63 Neutral	$3.99B	24.79	9.72%	0.29%	9.19%	23.06%
RGEN	60 Neutral	$6.41B	188.46	2.37%	―	11.74%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	46 Neutral	$8.31B	-10.24	-13.78%	2.75%	-21.20%	-325.40%

AptarGroup Corporate Events

AptarGroup Announces CEO Succession and Leadership Transition Plan

On March 16, 2026, AptarGroup announced that President and CEO Stephan Tanda will retire from his executive roles effective Sept. 1, 2026, with Aptar Pharma president Gael Touya appointed as his successor and expected to join the board at that time. Tanda will remain on the board and serve as a strategic adviser through Dec. 31, 2026, under a separate letter agreement that preserves his 2025-level pay and incentive opportunities during the transition period.

Touya’s new employment agreement runs initially through Dec. 31, 2028, with automatic one-year extensions, and provides for a $1.06 million base salary, enhanced annual and long-term incentive opportunities, relocation support, and detailed severance and change-in-control protections. As part of the leadership transition, AptarGroup also granted sizable retention equity awards to Chief Financial Officer Vanessa Kanu and Aptar Closures president Hedi Tlili, underscoring the board’s focus on continuity and stability across the senior management team.

The most recent analyst rating on (ATR) stock is a Hold with a $147.00 price target. To see the full list of analyst forecasts on AptarGroup stock, see the ATR Stock Forecast page.